Efficacy and safety of bevacizumab and platinum‑based chemotherapy as neoadjuvant regimen for stage‑IIIA non‑squamous non‑small cell lung cancer: A retrospective study

Jiang,Dexiong; Rao,Yao; Zhang,Chunxi; Wang,Dan; Jiang,Xu; Wang,Huachuan

doi:10.3892/ol.2024.14508

Efficacy and safety of bevacizumab and platinum‑based chemotherapy as neoadjuvant regimen for stage‑IIIA non‑squamous non‑small cell lung cancer: A retrospective study

Authors:
- Dexiong Jiang
- Yao Rao
- Chunxi Zhang
- Dan Wang
- Xu Jiang
- Huachuan Wang
View Affiliations

Affiliations: Pulmonary and Critical Care Medicine, Dazhou Central Hospital, Dazhou, Sichuan 635000, P.R. China, Department of Thoracic Surgery, Dazhou Central Hospital, Dazhou, Sichuan 635000, P.R. China
Published online on: June 13, 2024 https://doi.org/10.3892/ol.2024.14508
Article Number: 375
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Bevacizumab plus platinum‑based chemotherapy provides modest benefits in non‑squamous non‑small cell lung cancer (NSCLC), while its application as a neoadjuvant regimen has yet to be validated. The present study aimed to assess the efficacy of neoadjuvant bevacizumab plus platinum‑based chemotherapy in patients with stage‑IIIA non‑squamous NSCLC. Data from 110 patients with stage‑IIIA non‑squamous NSCLC with negative driver genes, who received neoadjuvant bevacizumab plus platinum‑based chemotherapy (n=50) or neoadjuvant platinum‑based chemotherapy alone (n=60), and tumor resection, were retrospectively reviewed in the current study. In addition, the data on pathological response, disease‑free survival (DFS), overall survival (OS) and adverse events were obtained. The results demonstrated that neoadjuvant bevacizumab plus chemotherapy did not significantly increase the pathological complete response (pCR) rate in comparison with neoadjuvant chemotherapy alone (18.0 vs. 8.3%; P=0.130). However, neoadjuvant bevacizumab plus chemotherapy significantly increased the rates of DFS (P=0.007) and OS (P=0.049) compared with neoadjuvant chemotherapy alone. Adjustments were then performed using multivariate logistic or Cox regression analyses, which demonstrated that neoadjuvant bevacizumab plus chemotherapy in comparison with neoadjuvant chemotherapy alone only significantly independently prolonged DFS [hazard ratio (HR)=0.251; P=0.042], but did not significantly affect pCR (odds ratio=2.897; P=0.117) or OS (HR=0.297; P=0.158). Furthermore, no significant differences were demonstrated between the number of adverse events in patients receiving neoadjuvant bevacizumab plus chemotherapy in comparison with those receiving neoadjuvant chemotherapy alone (all P>0.05). In conclusion, neoadjuvant bevacizumab plus platinum‑based chemotherapy was only associated with a significant improvement in the rate of DFS, but showed limited efficacy in improving pCR and OS rates in comparison with neoadjuvant chemotherapy alone in patients with stage‑IIIA non‑squamous NSCLC. Therefore, a larger sample size and randomized controlled studies are needed for further validation of the findings of the present study.

View Figures

View References

1	Zhu D, Shi X, Nicholas S, Ma Y and He P: Estimated annual prevalence, medical service utilization and direct costs of lung cancer in urban China. Cancer Med. 10:2914–2923. 2021. View Article : Google Scholar : PubMed/NCBI
2	Li C, Lei S, Ding L, Xu Y, Wu X, Wang H, Zhang Z, Gao T, Zhang Y and Li L: Global burden and trends of lung cancer incidence and mortality. Chin Med J (Engl). 136:1583–1590. 2023. View Article : Google Scholar : PubMed/NCBI
3	Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, D'Amico TA, et al: Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 20:497–530. 2022. View Article : Google Scholar : PubMed/NCBI
4	Chen P, Liu Y, Wen Y and Zhou C: Non-small cell lung cancer in China. Cancer Commun (Lond). 42:937–970. 2022. View Article : Google Scholar : PubMed/NCBI
5	Daly ME, Singh N, Ismaila N, Antonoff MB, Arenberg DA, Bradley J, David E, Detterbeck F, Fruh M, Gubens MA, et al: Management of stage III non-small-cell lung cancer: ASCO guideline. J Clin Oncol. 40:1356–1384. 2022. View Article : Google Scholar : PubMed/NCBI
6	Yoon SM, Shaikh T and Hallman M: Therapeutic management options for stage III non-small cell lung cancer. World J Clin Oncol. 8:1–20. 2017. View Article : Google Scholar : PubMed/NCBI
7	Nagasaka M and Gadgeel SM: Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer. Expert Rev Anticancer Ther. 18:63–70. 2018. View Article : Google Scholar : PubMed/NCBI
8	Bai R, Li L, Chen X, Chen N, Song W and Cui J: Neoadjuvant and adjuvant immunotherapy: Opening new horizons for patients with early-stage non-small cell lung cancer. Front Oncol. 10:5754722020. View Article : Google Scholar : PubMed/NCBI
9	Zhai J, Lu J, Zhang Z, Wang Y, Li X, Zhang S, Mu S, Zhi X, Ge X, Lu D, et al: First-line PD-1/PD-L1 inhibitors plus chemotherapy versus bevacizumab plus chemotherapy for advanced non-squamous non-small cell lung cancer: A Bayesian network meta-analysis of randomized controlled trials. Cancer Med. 11:2043–2055. 2022. View Article : Google Scholar : PubMed/NCBI
10	Garcia J, Hurwitz HI, Sandler AB, Miles D, Coleman RL, Deurloo R and Chinot OL: Bevacizumab (Avastin^®) in cancer treatment: A review of 15 years of clinical experience and future outlook. Cancer Treat Rev. 86:1020172020. View Article : Google Scholar : PubMed/NCBI
11	Varlotto JM, Wang Y, Sun Z, Wakelee HA, Ramalingam S and Schiller J: Bevacizumab's association with a decreased risk of brain metastases in ECOG-ACRIN E1505, a phase 3 randomized trial of adjuvant chemotherapy with or without bevacizumab in surgically resected NSCLC. JTO Clin Res Rep. 3:1002742022.PubMed/NCBI
12	Wakelee HA, Dahlberg SE, Keller SM, Tester WJ, Gandara DR, Graziano SL, Adjei AA, Leighl NB, Aisner SC, Rothman JM, et al: Adjuvant chemotherapy with or without bevacizumab in patients with resected non-small-cell lung cancer (E1505): An open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 18:1610–1623. 2017. View Article : Google Scholar : PubMed/NCBI
13	Chaft JE, Rusch V, Ginsberg MS, Paik PK, Finley DJ, Kris MG, Price KAR, Azzoli CG, Fury MG, Riely GJ, et al: Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers. J Thorac Oncol. 8:1084–1090. 2013. View Article : Google Scholar : PubMed/NCBI
14	Ou W, Li N, Wang SY, Li J, Liu QW, Huang QA and Wang BX: Phase 2 trial of neoadjuvant bevacizumab plus pemetrexed and carboplatin in patients with unresectable stage III lung adenocarcinoma (GASTO 1001). Cancer. 122:740–747. 2016. View Article : Google Scholar : PubMed/NCBI
15	Xie N, Qu YZ, Jiang HP and Yang XJ: Effect of preoperative of bevacizumab combined with platinum-containing neoadjuvant chemotherapy on the prognosis of patients with stage IIIA-N2 stage lung cancer surgery. Chin J Surg Oncol. 14:371–375. 2022.
16	Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman J, Chirieac LR, D'Amico TA, DeCamp MM, Dilling TJ, Dobelbower M, et al: Non-small cell lung cancer, version 5.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 15:504–535. 2017. View Article : Google Scholar : PubMed/NCBI
17	Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S, Mooney M, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247. 2009. View Article : Google Scholar : PubMed/NCBI
18	Travis WD, Dacic S, Wistuba I, Sholl L, Adusumilli P, Bubendorf L, Bunn P, Cascone T, Chaft J, Chen G, et al: IASLC multidisciplinary recommendations for pathologic assessment of lung cancer resection specimens after neoadjuvant therapy. J Thorac Oncol. 15:709–740. 2020. View Article : Google Scholar : PubMed/NCBI
19	Pataer A, Weissferdt A, Correa AM, Vaporciyan AA, Sepesi B, Heymach JV, Berezowska S, Cascone T and Swisher SG: Major pathologic response and prognostic score predict survival in patients with lung cancer receiving neoadjuvant chemotherapy. JTO Clin Res Rep. 3:1004202022.PubMed/NCBI
20	Mabeta P and Steenkamp V: The VEGF/VEGFR axis revisited: Implications for cancer therapy. Int J Mol Sci. 23:155852022. View Article : Google Scholar : PubMed/NCBI
21	Le X, Nilsson M, Goldman J, Reck M, Nakagawa K, Kato T, Ares LP, Frimodt-Moller B, Wolff K, Visseren-Grul C, et al: Dual EGFR-VEGF pathway inhibition: A promising strategy for patients with EGFR-mutant NSCLC. J Thorac Oncol. 16:205–215. 2021. View Article : Google Scholar : PubMed/NCBI
22	Dell'Amore A, Lomangino I, Tamburini N, Bongiolatti S, Parri NSF, Grossi W, Catelli C, Lorenzoni G, Gregori D, Nicotra S, et al: Video-assisted thoracoscopic lobectomy after neoadjuvant chemotherapy for non-small cell lung cancer: A multicenter propensity-matched study. Surg Endosc. 36:1466–1475. 2022. View Article : Google Scholar : PubMed/NCBI
23	Zhao L, Zhang L, Gong F and Xu J: Thoracoscopic radical resection in the treatment of NSCLC patients (stage IIIA) after neoadjuvant chemotherapy. J BUON. 26:313–319. 2021.PubMed/NCBI
24	Trukhin D, Poddubskaya E, Andric Z, Makharadze T, Bellala RS, Charoentum C, Yanez Ruiz EP, Fulop A, Hyder Ali IA, Syrigos K, et al: Efficacy, safety and immunogenicity of MB02 (bevacizumab biosimilar) versus reference bevacizumab in advanced non-small cell lung cancer: A randomized, double-blind, phase III study (STELLA). BioDrugs. 35:429–444. 2021. View Article : Google Scholar : PubMed/NCBI
25	Quintanilha JCF, Wang J, Sibley AB, Jiang C, Etheridge AS, Shen F, Jiang G, Mulkey F, Patel JN, Hertz DL, et al: Bevacizumab-induced hypertension and proteinuria: A genome-wide study of more than 1000 patients. Br J Cancer. 126:265–274. 2022. View Article : Google Scholar : PubMed/NCBI
26	Liu Y, Li HM and Wang R: Effectiveness and safety of adding bevacizumab to platinum-based chemotherapy as first-line treatment for advanced non-small-cell lung cancer: A meta-analysis. Front Med (Lausanne). 8:6163802021. View Article : Google Scholar : PubMed/NCBI
27	Zhou CH, Yang F, Jiang WJ, Zhang YC, Yang HY, Zeng L, Liu L, Xiong Y, Zeng FX, Wang Z and Yang N: Efficacy and safety of different doses of bevacizumab combined with pemetrexed and platinum in first-line treatment of advanced NSCLC: A retrospective-real world study. Front Pharmacol. 12:7271022021. View Article : Google Scholar : PubMed/NCBI
28	Ettinger DS, Wood DE, Aisner DL, Akerley W, Bauman JR, Bharat A, Bruno DS, Chang JY, Chirieac LR, DeCamp M, et al: NCCN guidelines^® insights: Non-small cell lung cancer, version 2.2023. J Natl Compr Canc Netw. 21:340–350. 2023. View Article : Google Scholar : PubMed/NCBI